Adalvo announced on October 27, 2026 that it acquired Enzene’s romiplostim biosimilar program. The program references Amgen’s NPLATE®, which is indicated to treat adult and chronic pediatric immune thrombocytopenia (ITP). Romiplostim, a Fc-peptide fusion protein (peptibody), is a thrombopoietin receptor agonist (TPO-RA). The acquisition combines Adalvo’s global development, regulatory and…
